10.05.2016 Views

Final Program

h6okmgq

h6okmgq

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

MONDAY • MAY 16 207<br />

L15<br />

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,<br />

DIVISION OF LUNG DISEASES, NIH<br />

ENDOTYPES AND PHENOTYPES: A BASIS FOR<br />

PRECISION-BASED MEDICINE IN COPD, THE<br />

SUBPOPULATIONS AND INTERMEDIATE OUTCOME<br />

MEASURES IN COPD STUDY (SPIROMICS)<br />

12:15 p.m. - 1:15 p.m. MOSCONE CENTER<br />

Target Audience<br />

Those with clinical or research responsibilities.<br />

Room 2006/2008 (West Building, Level 2)<br />

Objectives<br />

At the conclusion of this session, the participant will be able to:<br />

• understand and learn about imaging phenotyping of COPD;<br />

• learn about molecular phenotyping of COPD;<br />

• learn about clinical pheontyping of COPD.<br />

SPIROMICS is an NHLBI sponsored study that supports the prospective<br />

collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical<br />

data from subjects with COPD for the purpose of identifying subpopulations and<br />

intermediate outcome measures. Participants in this session will learn about<br />

new results from the SPIROMICS study that define new clinical subpopulations<br />

related to COPD, clinically relevant endotypes that affect risk, and potential<br />

intermediate markers that predict disease progression. The session will also<br />

provide information for early stage investigators and the investigative<br />

community on how to get involved with the study and access data.<br />

Chairing: R.G. Barr, MD, DrPH, New York, NY<br />

L. Postow, PhD, Bethesda, MD<br />

12:15 Overview of SPIROMICS Design<br />

R.G. Barr, MD, DrPH, New York, NY<br />

12:25 Signficance of Large and Small Airway Phenotypes<br />

M.K. Han, MD, MS, Ann Arbor, MI<br />

12:40 Identifying COPD Subpopulations Based on Symptoms and<br />

Molecular Signatures<br />

P.G. Woodruff, MD, MPH, San Francisco, CA<br />

12:55 SPIROMICS Imaging Phenotyping<br />

E.A. Hoffman, PhD, Iowa City, IA<br />

1:05 Identified Subpopulations Based on Unbiased Clustering<br />

E. Bleecker, MD, Winston-Salem, NC<br />

L16<br />

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,<br />

DIVISION OF LUNG DISEASES, NIH<br />

VIRUSES AND BACTERIA IN ASTHMA ACROSS THE<br />

AGES<br />

12:15 p.m. - 1:15 p.m. MOSCONE CENTER<br />

Room 2002/2004 (West Building, Level 2)<br />

Target Audience<br />

Providers of lung health, medical fellows in training, graduate, post-doctoral<br />

fellows and established scientists in basic research on lung biology, and<br />

infectious disease.<br />

Objectives<br />

At the conclusion of this session, the participant will be able to:<br />

• understand and learn new findings about the impact of nasal bacteria and<br />

viruses on respiratory illness severity and response to azithromycin therapy<br />

in preschool children with recurrent severe episodes of lower respiratory<br />

tract symptoms;<br />

• gain knowledge about differences in the bronchial bacterial microbiome in<br />

patients with allergies and asthma and characterize modifications in the<br />

microbiome associated with the use of inhaled corticosteroids in adults with<br />

asthma;<br />

• describe how treatment with inhaled corticosteroids alters the bronchial<br />

virome in adults with asthma.<br />

This session highlights findings from two AsthmaNet studies that investigated<br />

effects of inhaled corticosteroids (ICS) on bacterial microbiome and virome in<br />

adults and effects of the virome on respiratory illness severity and response to<br />

azithromycin therapy in children. Findings elucidate how two components of the<br />

microbiome - bacterial and viral - are impacted by treatment and how viruses<br />

influence severity of respiratory illness and treatment response. Management<br />

insights might emerge during the panel-audience discussion, e.g., composition<br />

of the baseline airway bacterial microbiome may shape the response to viral<br />

respiratory infection,as frequently one of the treatments prescribed is an ICS.<br />

Chairing: W.W. Busse, MD, Madison, WI<br />

J.P. Kiley, PhD, Bethesda, MD<br />

12:15 Viral and Bacterial Determinants of Illness Severity and<br />

Response to Azithromycin Therapy in Preschool Children<br />

D.J. Jackson, MD, Madison, WI<br />

12:30 Bronchial Bacterial Microbiome: Relationships to Allergy,<br />

Asthma, and Inhaled Corticosteroid Treatment<br />

Y.J. Huang, MD, Ann Arbor, MI<br />

12:45 Bronchial Virome: Effects of Inhaled Corticosteroid Treatment<br />

in Adults with Asthma<br />

A. Shifren, MD, St. Louis, MO<br />

1:00 General Discussion<br />

W.W. Busse, MD, Madison, WI<br />

L17<br />

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,<br />

DIVISION OF LUNG DISEASES, NIH<br />

EDUCATION RESEARCH IN SLEEP HEALTH AND<br />

SLEEP-CIRCADIAN BIOLOGY<br />

12:15 p.m. - 1:15 p.m. MOSCONE CENTER<br />

Room 2016/2018 (West Building, Level 2)<br />

Target Audience<br />

Health care providers, researchers, educators, and public stakeholders<br />

interested in innovative education tools, programs and platforms that will<br />

transfer health information and scientific advances in sleep and circadian<br />

biology to medical education, health care, and community-based settings.<br />

MONDAY MID-DAY<br />

ATS 2016 • San Francisco

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!